If you made any changes in Pure these will be visible here soon.

Research Output

  • 22 Journal article
  • 17 Conference abstract in journal
  • 2 Poster
  • 1 Conference article in Journal
Filter
Conference abstract in journal
2020

Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer—A randomized controlled chemotherapy-free study.

Mirza, M. R., Nyvang, G-B., Lund, B., Christensen, R. D., Werner, T. L., Malander, S., Bjørge, L., Birrer, M. J., Anttila, M., Lindahl, G., Hietanen, S., Dimoula, M., Peen, U., Madsen, K., Knudsen, A., Staff, S., Buchner Vinum, N., Kjeldsen, M. K., Avall-Lundqvist, E. & Maenpaa, J. U., 2020, In : Journal of Clinical Oncology. 38, 15, suppl., p. 6012-6012 1 p.

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Niraparib exposure-response relationship in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)

Monk, B. J., Romero, I., Graybill, W., Churruca, C., O'Malley, D. M., Lund, B., Yap, O. W. S., Baurain, J-F., Rose, P. G., denys, H., Ghamande, S. A., Pisano, C., Fabbro, M., Braicu, E. I., Calvert, P., Amit, A., Prendergast, E., Milton, A., Zhang, Z-Y. & Gonzalez Martin, A., 2020, In : Journal of Clinical Oncology. 38, 15, suppl., p. 6051 1 p.

Research output: Contribution to journalConference abstract in journalResearchpeer-review

2019

Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free study-NSGO-AVANOVA2/ENGOT-OV24.

Mirza, M. R., Avall-Lundqvist, E., Birrer, M. J., Christensen, R. D., Nyvang, G-B., Malander, S., Anttila, M., Werner, T. L., Lund, B., Lindahl, G., Hietanen, S., Peen, U., Dimoula, M., Roed, H., Knudsen, A. O., Boufercha, L., Staff, S., Vistisen, A. K., Bjorge, L. & Maenpaa, J. U., 20 May 2019, In : Journal of Clinical Oncology. 37, 15, Suppl., 5505.

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Niraparib therapy in patients with newly diagnosed advanced ovarian cancer (PRIMA/ENGOT-OV26/GOG-3012 study)

Gonzalez Martin, A., Pothuri, B., Vergote, I. B., Christensen, R. D., Graybill, W., Mirza, M. R., McCormick, C., Lorusso, D., Hoskins, P., Freyer, G., Backes, F., Baumann, K., Redondo, A., Moore, R. G., Vulsteke, C., O'Cearbhaill, R. E., Lund, B., Li, Y., Gupta, D. & Monk, B. J., 1 Oct 2019, In : Annals of Oncology. 30, Suppl. 5, p. 893-893 1 p.

Research output: Contribution to journalConference abstract in journalResearchpeer-review

2018

A time without symptoms or toxicity analysis of niraparib compared with routine surveillance in the maintenance treatment of patients with recurrent ovarian cancer

Mirza, M. R., Walder, L., Monk, B. J., Tinker, A. V., Mahner, S., Gil-Martin, M., Kalbacher, E., Waters, J., Wenham, R. M., Malander, S., Gilbert, L., Sehouli, J., Casado Herraez, A., Hardy-Bessard, A., Williams, S. J., Rimel, B. J., Lund, B., Levy, T., Guy, H. & Matulonis, U. A., Oct 2018, In : Value in Health. 21, Suppl. 3, p. S16 PCN7.

Research output: Contribution to journalConference abstract in journalResearchpeer-review

2017

Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: Results from the ENGOT-OV16/NOVA trial

Oza, A. M., Matulonis, U. A., Malander, S., Sehouli, J., del Campo, J. M., Berthon-Rigaud, D., Banerjee, S., Scambia, G., Berek, J. S., Lund, B., Tinker, A. V., Hilpert, F., Palacio Vázquez, I., D’hondt, V., Benigno, B., Provencher, D. M., Buscema, J., Hudgens, S., Agarwal, S. & Mirza, M. R., 2017, In : Annals of Oncology. 28, Suppl. 5, p. 330 1 p., 930O.

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Open Access
2016

An Open-Labelled, Randomized Phase II Study in Patients with Recurrent Glioblastoma Multiforme Comparing Progression Free Survival of Alecsat (Autologous Lymphoid Effector Cells Specific Against Tumour-Cells) Versus Bevacizumab/irinotecan

Haslund, C., Muhic, A., Lukacova, S., Lund, B., Lassen-Ramshad, Y., Meyer, M., Roland, M. & Poulsen, H. S., 1 Oct 2016, In : Neuro-Oncology. 18, p. iv6 1 p.

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Circulating tumor cell number predicts time to progression (TTP) in patients with heavily pretreated gynecological cancers treated with selinexor (SEL)

Crochiere, M., Vergote, I. B., Lund, B., Havsteen, H., Ujmajuridze, Z., Van Nieuwenhuysen, E., Haslund, C., Juhler-Nottrup, T., Mau-Sorensen, M., Berteloot, P., Kranich, A. L., Meade, J., Wright, G., Shacham, E., Rashal, T., Saint-Martin, J-R., Shacham, S., Kauffman, M., Mirza, M. R. & Landesman, Y., 2016, In : Annals of Oncology. 27, Suppl. 6, 886P.

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Results of a phase 2 trial of selinexor, an oral selective inhibitor of nuclear export (SINE) in 114 patients with gynaecological cancers

Vergote, I., Lund, B., Havsteen, H., Ujmajuridze, Z., Van Nieuwenhuysen, E., Haslund, C., Juhler-Nottrup, T., Neven, P., Mau-Sorensen, M., Berteloot, P., Kranich, A. L., Rashal, T., Meade, J., Landesman, Y., Saint-Martin, J-R., Wright, G., Crochiere, M., Shacham, S., Kauffman, M. & Mirza, M. R., 2016, In : Annals of Oncology. 27, Suppl. 6, 8540O.

Research output: Contribution to journalConference abstract in journalResearchpeer-review

1 Citation (Scopus)
2015

Preliminary phase II results of selinexor, an oral selective inhibitor of nuclear export in patients with heavily pretreated gynecological cancers

Vergote, I., Lund, B., Havsteen, H., Ujmajuridze, Z., Leunen, K., Haslund, C. A., Juhler-Nøttrup, T., Roed, H., Rashal, T., Kranich, A. L., Landesman, Y., Saint-Martin, J-R., Carlson, R., Shacham, S., Kauffman, M. & Mirza, M. R., 2015, In : Journal of Clinical Oncology. 33, 15 Suppl., TPS5565.

Research output: Contribution to journalConference abstract in journalResearchpeer-review

2014

Disease relapse in ovarian cancer patients detected by HE4 and CA125

Steffensen, K. D., Waldstrøm, M., Brandslund, I., Lund, B., Sørensen, S. M., Petzold, M. & Jakobsen, A., 2014, In : International Journal of Gynecological Cancer. 29, 9, 4 suppl., p. 189

Research output: Contribution to journalConference abstract in journalResearchpeer-review

KCP-330-005/SIGN: A phase II, open-label study of efficacy and safety of the selective inhibitor of nuclear export (SINE) KPT-330 (SELINEXOR) in patients with advanced gynaecologic malignancies

Vergote, I., Lund, B., Ujmajuridze, Z., Havsteen, H., Rashal, T., McCartney, J., Kauffman, M., Shacham, S. & Mirza, M. R., 2014, In : International Journal of Gynecological Cancer. 29, 9, 4 suppl., p. 1182

Research output: Contribution to journalConference abstract in journalResearchpeer-review

2012

Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: The PaLiDo study, a phase II nonrandomized multicenter study.

Steffensen, K. D., Waldstrom, M., Pallisgård, N., Lund, B., Bergfeldt, K., Wihl, J., Keldsen, N., Marth, C., Vergote, I. B. & Jakobsen, A. K. M., 20 May 2012, In : Journal of Clinical Oncology. 30, 15

Research output: Contribution to journalConference abstract in journalResearchpeer-review

2011

18F-FDG PET/CT prediction of malignant versus benign lesion in patients presenting with adnexal mass

Frost, M., Iyer, V. V., Fisker, R. V., Andersen, E. S., Grove, A., Lund, B. & Noer, I., 2011, In : The Journal of Nuclear Medicine. 52, p. 2310

Research output: Contribution to journalConference abstract in journalResearch

2010

Health-related quality of life (HRQL) and progression-free survival (PFS) in patients with recurrent ovarian cancer: Results from the CALYPSO trial

Brundage, M., Gropp, M., Mefti, F., Mann, M. K., Lund, B., Gebeski, V., Wolfram, G., Reed, N., Pignata, S. & Ferrero, A., 20 May 2010, In : Journal of Clinical Oncology. 28, 15, 5044.

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Panitumumab and pegylated liposomal doxorubicin to platinum-resistant epithelial ovarian cancer with KRAS wild-type: An ongoing, nonrandomized, multicenter, phase II trial.

Steffensen, K. D., Waldstrøm, M., Lund, B., Bergfeldt, K., Keldsen, N., Marth, C., Vergote, I. B. & Jakobsen, A. K., 2010, In : Journal of Clinical Oncology. 28, 15suppl, TPS254.

Research output: Contribution to journalConference abstract in journalResearchpeer-review

2006

Pegylated liposomal doxorubicin (PLD) and gemcitabine (GEM) in combination in the salvage treatment of epithelial ovarian cancer (OC)—a Danish Gynaecologic Cancer Group (DGC) study

Mirza, M. R., Lund, B., Bertelsen, K., Lindegaard, J., Keldsen, N., Mellemgaard, A. & Depont, R., 20 Jun 2006, In : Journal of Clinical Oncology. 24, 18_suppl, 1 p., 5094.

Research output: Contribution to journalConference abstract in journalResearchpeer-review